Your browser doesn't support javascript.
loading
EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.
Etemadmoghadam, Dariush; Azar, Walid J; Lei, Ying; Moujaber, Tania; Garsed, Dale W; Kennedy, Catherine J; Fereday, Sian; Mitchell, Chris; Chiew, Yoke-Eng; Hendley, Joy; Sharma, Raghwa; Harnett, Paul R; Li, Jason; Christie, Elizabeth L; Patch, Ann-Marie; George, Joshy; Au-Yeung, George; Mir Arnau, Gisela; Holloway, Timothy P; Semple, Timothy; Pearson, John V; Waddell, Nicola; Grimmond, Sean M; Köbel, Martin; Rizos, Helen; Lomakin, Ivan B; Bowtell, David D L; deFazio, Anna.
Afiliação
  • Etemadmoghadam D; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Azar WJ; Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • Lei Y; Department of Pathology, University of Melbourne, Melbourne, Victoria, Australia.
  • Moujaber T; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Garsed DW; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
  • Kennedy CJ; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Fereday S; The University of Sydney, Sydney, New South Wales, Australia.
  • Mitchell C; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
  • Chiew YE; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Hendley J; The University of Sydney, Sydney, New South Wales, Australia.
  • Sharma R; Crown Princess Mary Cancer Care Centre, Westmead Hospital, Sydney, New South Wales, Australia.
  • Harnett PR; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Li J; Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • Christie EL; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
  • Patch AM; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
  • George J; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Au-Yeung G; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Mir Arnau G; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
  • Holloway TP; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Semple T; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Pearson JV; The University of Sydney, Sydney, New South Wales, Australia.
  • Waddell N; Pathology West ICPMR, Westmead, New South Wales, Australia.
  • Grimmond SM; The University of Western Sydney at Westmead Hospital, Westmead, New South Wales, Australia.
  • Köbel M; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
  • Rizos H; The University of Sydney, Sydney, New South Wales, Australia.
  • Lomakin IB; Crown Princess Mary Cancer Care Centre, Westmead Hospital, Sydney, New South Wales, Australia.
  • Bowtell DDL; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • deFazio A; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Cancer Res ; 77(16): 4268-4278, 2017 08 15.
Article em En | MEDLINE | ID: mdl-28646021
Low-grade serous ovarian carcinomas (LGSC) are associated with a poor response to chemotherapy and are molecularly characterized by RAS pathway activation. Using exome and whole genome sequencing, we identified recurrent mutations in the protein translational regulator EIF1AX and in NF1, USP9X, KRAS, BRAF, and NRAS RAS pathway mutations were mutually exclusive; however, we found significant co-occurrence of mutations in NRAS and EIF1AX Missense EIF1AX mutations were clustered at the N-terminus of the protein in a region associated with its role in ensuring translational initiation fidelity. Coexpression of mutant NRAS and EIF1AX proteins promoted proliferation and clonogenic survival in LGSC cells, providing the first example of co-occurring, growth-promoting mutational events in ovarian cancer. Cancer Res; 77(16); 4268-78. ©2017 AACR.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Fator de Iniciação 1 em Eucariotos / Cistadenocarcinoma Seroso / GTP Fosfo-Hidrolases / Proteínas de Membrana / Mutação Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Fator de Iniciação 1 em Eucariotos / Cistadenocarcinoma Seroso / GTP Fosfo-Hidrolases / Proteínas de Membrana / Mutação Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Austrália
...